Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy

15 Apr 2024

Abstract excerpt

Complement inhibitors are the mainstay of paroxysmal nocturnal hemoglobinuria (PNH) treatment. The anti-C5 monoclonal antibody eculizumab was the first treatment to improve hemolysis, thrombotic risk, and survival in PNH although at the price of a life-long intravenous fortnightly drug. Additionally, suboptimal response may occur in up to 2/3 of patients with persistent anemia due to incomplete control of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Coagulation, Bradykinin, Polyphosphates, and Angioedema
Share to Complement system in diseases
Share to Renal Diseases and Glomerulopathies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38622956
DOI: 10.1111/ijlh.14281

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapyPMID 38622956Read ↗

With complements: C3 inhibition in the clinicSemantic proximity Read ↗

Paroxysmal Nocturnal Hemoglobinuria: Unraveling Its Molecular Pathogenesis and Advancing Targeted Therapeutic StrategiesSemantic proximity Read ↗

Complement C5 inhibitor crovalimab for the treatment of paroxysmal nocturnal hemoglobinuria.Semantic proximity Read ↗

Current status and perspectives of hematopoietic cell transplantation in patients with paroxysmal nocturnal hemoglobinuriaSemantic proximity Read ↗

How we('ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future.Semantic proximity Read ↗

Protein therapeutics and their lessons: Expect the unexpected when inhibiting the multi‐protein cascade of the complement systemSemantic proximity Read ↗

Paroxysmal Nocturnal Hemoglobinuria: Biology and TreatmentSemantic proximity Read ↗

Monitoring of patients with paroxysmal nocturnal hemoglobinuria on a complement inhibitorSemantic proximity Read ↗

Management of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitory therapy.Semantic proximity Read ↗

The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal HemoglobinuriaSemantic proximity Read ↗

[Paroxysmal nocturnal hemoglobinuria: from physiopathology to treatment].Semantic proximity Read ↗

Complement biology for hematologistsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.